INS and Alzheimer disease: In AD, there is a general alteration in metabolism, with changes in short-chain fatty acid (SCFA) (62) and bile acid (63) levels, as well as dysregulation of glucose metabolism and cerebral insulin resistance (64), which have been implicated in cognitive decline and amyloid accumulation (65).